These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 18236358)
41. Studies of diabetes, thiazolidinediones, and coronary heart disease. Walker AM; McAfee AT; Koro C Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1313-4; author reply 1314-6. PubMed ID: 18041104 [No Abstract] [Full Text] [Related]
42. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes. Lehmann DF; Lohray BB J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500 [No Abstract] [Full Text] [Related]
43. The current role of thiazolidinediones in diabetes management. Rizos CV; Kei A; Elisaf MS Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418 [TBL] [Abstract][Full Text] [Related]
44. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view]. MMW Fortschr Med; 2008 Aug; 150(32-35):56-7. PubMed ID: 19009700 [No Abstract] [Full Text] [Related]
45. The PROactive study: some answers, many questions. Yki-Järvinen H Lancet; 2005 Oct; 366(9493):1241-2. PubMed ID: 16214581 [No Abstract] [Full Text] [Related]
46. Rosiglitazone and cardiovascular risk. Diamond GA; Kaul S N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135 [No Abstract] [Full Text] [Related]
47. Pioglitazone and lung cancer risk in Taiwanese patients with type 2 diabetes. Tseng CH Diabetes Metab; 2018 Feb; 44(1):77-79. PubMed ID: 28684163 [No Abstract] [Full Text] [Related]
52. Diabetes prevention: still no effective drugs. Prescrire Int; 2007 Dec; 16(92):258. PubMed ID: 18095391 [TBL] [Abstract][Full Text] [Related]
53. FDA puts restrictions on use of controversial diabetes drug. Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371 [No Abstract] [Full Text] [Related]
54. [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review]. Madsbad S Ugeskr Laeger; 2007 Nov; 169(47):4054-7. PubMed ID: 18078659 [No Abstract] [Full Text] [Related]
55. [The true place of glitazones in the treatment of diabetes: after the PROactive study]. Lindberg M; Jørgensen PH; Kampmann JP Ugeskr Laeger; 2006 Jun; 168(25):2477-9; author reply 2479-80. PubMed ID: 16824389 [No Abstract] [Full Text] [Related]
56. The record on rosiglitazone and the risk of myocardial infarction. Psaty BM; Furberg CD N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162 [No Abstract] [Full Text] [Related]
57. Pioglitazone and bladder cancer: the pros and cons. Panikar V J Assoc Physicians India; 2012 Jan; 60():72-3. PubMed ID: 22715550 [No Abstract] [Full Text] [Related]
58. [Doubts as to the cardiovascular safety of rosiglitazone]. Wolffenbuttel BH Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2236-7; author reply 2237. PubMed ID: 17969577 [No Abstract] [Full Text] [Related]
59. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy]. MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688 [No Abstract] [Full Text] [Related]
60. Cardiovascular risk and the thiazolidinediones: déjà vu all over again? Solomon DH; Winkelmayer WC JAMA; 2007 Sep; 298(10):1216-8. PubMed ID: 17848659 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]